Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure
NCT ID: NCT05223751
Last Updated: 2025-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
65 participants
INTERVENTIONAL
2022-02-07
2025-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying and Facilitating Ventricular Recovery on Mechanical Support
NCT00687856
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
NCT05040451
Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial
NCT00382863
Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery
NCT00769678
NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)
NCT05375110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur.
* Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breathing therapy) or the control (standard of care).
* N-terminal (NT)-pro hormone BNP (NT-proBNP): If an NT-proBNP was collected as standard of care within 3 months of enrollment, this can be used for study purposes and compared to the 6 month NT-proBNP.
* New York Heart Association Class: If the NYHA class is completed as standard of care within 3 months of enrollment, this can be used for study proposes.
* Kansas City Cardiomyopathy Questionnaire (KCCQ)
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Orientation to the Heart Rate Variability 4 (HRV4) Training application: This will include downloading, creating an account for, and training the participant on the application.
The Intervention Group will also receiving training on the Meo Health breathing therapy, which will include:
* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and custom setting the Breathe application.
* Zoom Within one month of the baseline visit, participants in the intervention group will have a one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their breathing therapy intervention.
3 Month Visit The 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group . The participant will only meet with the CRC at the 3 month visit and all assessments will be completed by the CRC.
* NYHA class
* KCCQ
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Assess compliance from HRV4 Training application questions
* Assess any possible adverse events
6 Month/Final Visit The 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group. The participant will meet with the CRC at the 6 month visit, any assessments not completed as Standard of Care (SOC), will be completed by the CRC.
* NT-proBNP: If an NT-proBNP is ordered as standard of care for the participant, this can be used for study purposes and compared to the baseline NT-proBNP.
* NYHA class: If the NYHA class is completed as standard of care, this can be used for study purposes and compared to the baseline and 3 month values.
* KCCQ
* Respiratory Rate
* Peak Expiratory Flow
* 6-minute walk test
* Assess any possible adverse events
9 Month Structured Telephone Survey The 9 month structured telephone interview will take place for all participants who receive breathing training from Meo Health. Participants will be called by a study team member who will facilitate a short (3-5 minute) telephone survey about adherence and changes in health outcomes as a result of participation in the trial. (See appendix 15.4). The study team member will record all answers into REDCap. Upon completion of the survey, participants will be closed out of the study. If a study team member is unable to get in contact with a participant after two attempts, their status will be marked as "closed to follow-up" and they won't be interviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HRV4 + Breathing and Humming Training
On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.
Meo Health Breathing and humming exercises
The Intervention Group will receive training on the Meo Health breathing therapy, which will include:
* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.
* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.
Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.
A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.
A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.
HRV4 Only
Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meo Health Breathing and humming exercises
The Intervention Group will receive training on the Meo Health breathing therapy, which will include:
* Being shown the Meo Health Breathing Therapy On-Boarding video
* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.
* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.
Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.
A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.
A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signed informed consent
3. NYHA class II-III heart failure
4. EF ≤ 45% (echo within 1 year of enrollment)
5. At least 30 days of stable medical regimen (no new neurohormonal blockade or Sodium-glucose co-transporter 2 inhibitors (SGLT2i). Dose adjustments allowed)
6. Likely to be compliant with breath training as assessed by the provider
7. Availability of a "smart" phone and internet access
8. Established care at Lancaster General Health Penn Medicine
Exclusion Criteria
2. Severe Chronic obstructive pulmonary disease (COPD)
3. History of diaphragm paralysis
4. Unable or unwilling to complete respiratory training protocol
5. Decompensated or American College of Cardiology (ACC) Stage D Heart Failure (HF)
6. Prior or planned chest/abdominal or nasal/facial surgery within 6 months
7. Neuromuscular disease which impairs respiration
8. Diagnosed cognitive impairment (unable to participate in training)
9. Untreated obstructive severe sleep apnea (AHI \> 30)
10. Severe valvular heart disease
11. Uncontrolled atrial fibrillation (Ave Heart Rate (HR) \> 100 bpm)
12. Orthopedic or other limitations which impair the 6-minute walk test
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Louise von Hess Medical Research Institute
OTHER
Lancaster General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roy Small, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lancaster General Hospital
Lancaster, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-XXXX-LGHP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.